Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Pfizer Inc. (PFE): Hedge Funds Are Bullish and Insiders Are Bearish, What Should You Do?

Page 1 of 2

Is Pfizer Inc. (NYSE:PFE) a buy, sell, or hold? Hedge funds are buying. The number of long hedge fund positions inched up by 3 in recent months.

To the average investor, there are a multitude of gauges market participants can use to analyze their holdings. A duo of the most underrated are hedge fund and insider trading activity. At Insider Monkey, our studies have shown that, historically, those who follow the best picks of the top investment managers can trounce the broader indices by a superb amount (see just how much).

Pfizer Inc. (NYSE:PFE)Equally as beneficial, optimistic insider trading sentiment is another way to break down the investments you’re interested in. There are a number of stimuli for an upper level exec to drop shares of his or her company, but only one, very clear reason why they would buy. Many academic studies have demonstrated the valuable potential of this strategy if investors know what to do (learn more here).

Consequently, it’s important to take a glance at the recent action encompassing Pfizer Inc. (NYSE:PFE).

How have hedgies been trading Pfizer Inc. (NYSE:PFE)?

At the end of the first quarter, a total of 81 of the hedge funds we track held long positions in this stock, a change of 4% from the previous quarter. With the smart money’s sentiment swirling, there exists an “upper tier” of key hedge fund managers who were increasing their holdings substantially.

According to our comprehensive database, Ken Fisher’s Fisher Asset Management had the biggest position in Pfizer Inc. (NYSE:PFE), worth close to $886.3 million, accounting for 2.4% of its total 13F portfolio. The second largest stake is held by Rob Citrone of Discovery Capital Management, with a $508.1 million position; 6.8% of its 13F portfolio is allocated to the stock. Other peers that hold long positions include Donald Yacktman’s Yacktman Asset Management, Phill Gross and Robert Atchinson’s Adage Capital Management and Donald Chiboucis’s Columbus Circle Investors.

With a general bullishness amongst the heavyweights, specific money managers have jumped into Pfizer Inc. (NYSE:PFE) headfirst. Mason Capital Management, managed by Kenneth Mario Garschina, established the most valuable position in Pfizer Inc. (NYSE:PFE). Mason Capital Management had 165.4 million invested in the company at the end of the quarter. Paul Tudor Jones’s Tudor Investment Corp also made a $52.7 million investment in the stock during the quarter. The following funds were also among the new PFE investors: Matthew Tewksbury’s Stevens Capital Management, Charles Clough’s Clough Capital Partners, and Howard Guberman’s Gruss Asset Management.

What have insiders been doing with Pfizer Inc. (NYSE:PFE)?

Bullish insider trading is particularly usable when the company we’re looking at has seen transactions within the past 180 days. Over the latest six-month time period, Pfizer Inc. (NYSE:PFE) has seen zero unique insiders purchasing, and 11 insider sales (see the details of insider trades here).

Let’s also examine hedge fund and insider activity in other stocks similar to Pfizer Inc. (NYSE:PFE). These stocks are GlaxoSmithKline plc (ADR) (NYSE:GSK), Merck & Co., Inc. (NYSE:MRK), Sanofi SA (ADR) (NYSE:SNY), Johnson & Johnson (NYSE:JNJ), and Novartis AG (ADR) (NYSE:NVS). This group of stocks belong to the drug manufacturers – major industry and their market caps are closest to PFE’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!